Malaria vaccine development—where are we? thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Malaria vaccines: a new approach for an old idea biomedcentral.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biomedcentral.com Daily Mail and Mail on Sunday newspapers.
Two chemoattenuated PfSPZ malaria vaccines provide strong and lasting protection
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and
Plasmodium malariae.
In 2019 alone, over 229 million cases of malaria were reported globally, with about 409,000 deaths due to this disease. Although several drug and anti-vector measures have been developed to mitigate the morbidity and mortality associated with malaria, the progress in combatting this disease has stalled.
The Mosquirix (RTS,S) and Sanaria
Plasmodium falciparum sporozoites (PfSPZ) vaccines are considered the most advanced candidates for conferring sterile protective immunity against malaria. The RTS,S vaccine targets the circumsporozoite protein (CSP) of PfSPZ and has demonstrated its ability to provide partial protection against clinical malaria.
Sanaria researchers make progress in the development of highly protective malaria vaccine
Researchers from Sanaria
® Inc. and the National Institutes of Health (NIH) are making progress in the development of highly protective malaria vaccines.
In an article published today in
Nature, Sanaria s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.
The variant parasite used in the trial is a Brazilian malaria parasite genetically more variant from the African parasites in the vaccine than 700 malaria parasites from Africa. Protection was achieved at a dose that is 20% of the company s first-generation malaria vaccine dosage.
Sanaria Vaccine trial results demonstrate unprecedented progress in worldwide battle against variant malaria parasites pulse.ng - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pulse.ng Daily Mail and Mail on Sunday newspapers.